What on Earth is happening with Mesoblast shares today?

First it was jumping and then it was sinking. What's going on?

| More on:
A woman in her late 30s holds her hands out either side with the palms up as if indicating she doesn't know the answer to a question. She has a quizzical look on her face.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mesoblast Ltd (ASX: MSB) shares are having a volatile session on Thursday.

At one stage, the biotechnology company's shares were up over 6% to a 52-week high of $1.87.

It has now given back these gains and dropped 6% to $1.65.

Why are Mesoblast shares falling?

Investors were buying and then selling the company's shares today after the allogeneic cellular medicines developer made a major announcement.

According to the release, the United States Food and Drug Administration (FDA) has granted its second generation allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell therapy Revascor Regenerative Medicine Advanced Therapy (RMAT) designation.

This follows the submission of results from a randomised controlled trial in children with hypoplastic left heart syndrome (HLHS).

HLHS is a severe congenital heart disease in which the left side of the heart does not fully develop and effective pumping of oxygenated blood by the left ventricle to the rest of the body is reduced.

Mesoblast notes that without immediate surgery after birth, the prognosis is dismal with HLHS overall being responsible for 25% to 40% of all neonatal cardiac mortality.

Earlier this year, FDA granted Revascor both Rare Pediatric Disease Designation (RPDD) and OrphanDrug Designation (ODD) for treatment of children with HLHS.

What is RMAT designation?

The release notes that RMAT designations aim to expedite the development of regenerative medicine therapies that aim to treat, modify, reverse, or cure a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for the disease or condition.

The company highlights that an RMAT designation for Revascor -L provides all the benefits of Breakthrough and Fast Track designations, including rolling review and eligibility for priority review on filing of a Biologics License Application (BLA).

Furthermore, on FDA approval of a BLA for Revascor for the treatment of HLHS, Mesoblast may be eligible to receive a Priority Review Voucher (PRV). This can be redeemed for any subsequent marketing application or may be sold or transferred to a third party.

PRVs are regularly sold for more than US$100 million.

Commenting on the news, Mesoblast's chief executive Silviu Itescu, revealed that he was pleased with the news. He said:

We appreciate FDA's support in designating REVASCOR both RMAT and RPD status, a recognition of the potential impact of our therapy on the long-term adverse outcomes of these desperately ill children. Under the RMAT designation, we plan to meet with FDA to discuss a potential approval pathway in this indication.

It seems that today's decline has been a case of 'buy the rumour and sell the news'.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »